SEC Tracker
Get the app

Dare Bioscience DARE

Dare Bioscience (Dare) has filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational progress. The filing highlights continued development of Dare's pipeline of women's health products, including positive clinical trial results for its lead candidate. This quarterly report offers valuable insights into Dare's near-term business outlook and ability to execute on its strategic priorities.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Dare Bioscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025